// App-Quantinova.ai

1316 : A novel class of T cell-activating antibody that selectively targets the TCR b chain to promote antitumor activity through activation and expansion of a novel, polyclonal effector memory T cell subset

Researchers

Presenter

  • Andy Bayliffe

Principal Investigators

  • Zhen Su

  • John Wherry

  • Jonathan Hsu

  • Madan Katraggada

  • Jacques Moisan

  • GURKAN GUNTAS

  • Karunya Srinivasan

  • Jessica Lowry

  • Rajesh Chopra

  • Roya Servattalab

  • Wei Huang

  • Jian Tang

Medical Centers

  • Apple Tree Partners, London, UK

  • Sigilon Therapeutics, Cambridge, MA, USA

  • University of Pennsylvania, Philadelphia, PA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • tumor-infiltrating lymphocytes

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved